Cargando…
Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6
BACKGROUND: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. The aim was to determine the association of CYP2D6 phenotype with the risk...
Autores principales: | Takahashi, Paul Y, Ryu, Euijung, Pathak, Jyotishman, Jenkins, Gregory D, Batzler, Anthony, Hathcock, Matthew A, Black, John Logan, Olson, Janet E, Cerhan, James R, Bielinski, Suzette J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317339/ https://www.ncbi.nlm.nih.gov/pubmed/28243137 http://dx.doi.org/10.2147/PGPM.S114211 |
Ejemplares similares
-
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
por: Takahashi, Paul Y, et al.
Publicado: (2021) -
Quantifying the importance of disease burden on perceived general health and depressive symptoms in patients within the Mayo Clinic Biobank
por: Ryu, Euijung, et al.
Publicado: (2015) -
Health behaviors and quality of life predictors for risk of hospitalization in an electronic health record-linked biobank
por: Takahashi, Paul Y, et al.
Publicado: (2015) -
Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Response to Letter]
por: Takahashi, Paul Y, et al.
Publicado: (2021) -
Acceptability of Electronic Visits for Return of Research Results in the Mayo Clinic Biobank
por: Olson, Janet E., et al.
Publicado: (2018)